Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1 Further upgraded FY 2026 financial guidance: total sales growth around 23.0% at CER (prior guidance: greater than 20.0% at CER); core operating margin around 39.0% of total sales (prior guidance: greater than 37.0%) Multiple late-stage pipeline assets with blockbuster potential in Oncology, Rare Disease and Neuroscience, strengthening Ipsen’s future growth profilePARIS, FRANCE, 22 October 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026.                YTD2026 YTD2025 %change Q32026 Q32025 %change€m €m Actual CER €m €m Actual CEROncology 2,196.9 1,912.0         14.9%                 16.3%         745.4 624.0         19.4%                 17.7%        Rare...

(2026-10-22) Kitron today reported strong growth in revenue and operating profit, along with a record order backlog, reflecting robust demand across market sectors. Kitron’s revenue for the third quarter was EUR 266.8 million, an increase of 59 per cent from 167.8 million in the same quarter last year. The Defence/Aerospace market sector continued to show an exceptional increase from last year, but there was solid progress across other market sectors as well. Third-quarter operating profit (EBIT) was EUR 25.2 million, compared with 14.6 million in the same quarter last year, an increase of 73 per cent. Profitability expressed as EBIT margin was 9.5 per cent, compared with 8.7 per cent in the same quarter last year. This is in line with the strategic target of maintaining an EBIT margin above 9 per cent. The order backlog ended at...

9M 2026 financial informationExceptionally high momentum in PWR-Grid and PWR-ConnectPWR-Transmission continued growth normalization while margin will continue to improve in FY 2026 Integration of Republic Wire in the U.S. well on trackSuccessful completion of €500 million bond issuance2026 guidance confirmedStandard sales approached the €5 billion milestone in first nine months of 2026. 9M 2026 Group organic growth at +3.9%, including a high +9.0% organic growth in Q3 2026Standard sales of €4,946.7 million in the first nine months of 2026, up +10.1% year on year, including +3.9% organic growth, +5.6% scope contribution thanks to acquisitions and +0.6% foreign exchange effect Electrification businesses up +12.9% in the first nine months of 2026, including +5.3% organically and +6.6% related to scope, and up +7.1% organically in the...

After a record first half, Kinepolis strengthens its lead in the third quarter Regulated information 22 October 2026, 07:00 CET Kinepolis delivered record results in the third quarter, recording a 49.1% increase in visitor attendance, driven by an exceptionally successful summer film slate and the expansion of its U.S. footprint. As a result, the Group further widened its lead over 2025, both in terms of attendance and financial performance.  The success of ‘The Odyssey’ and ‘Spider-Man: Brand New Day’, among others, drove significant like-for-like visitor and revenue growth, despite adverse exchange rate effects from the Canadian and U.S. dollar versus the euro. Revenue per visitor continued to increase, driven by higher in-theatre sales per visitor and the success of premium cinema experiences such as IMAX and ScreenX. Continued cost...

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025 Tightened 2026 total revenue guidance to US$380 million – US$390 million from prior US$375 million – US$395 million Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDTLeiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announces preliminary, unaudited revenue and select financial information for the three months ended September 30, 2026. Pharming...

OSLO, Norway (22 October 2026) – TGS today reports interim financial results for Q3 2026. Financial highlights:Revenues of USD 397 million driven by high contract activity, compared to USD 388 million in Q3 2025  EBITDA of USD 222 million, including USD 41 million in gain from sale of the well data business, compared to USD 242 million in Q3 2025 EBIT of USD 86 million, including USD 41 million in gain from sale of the well data business, compared to USD 94 million in Q3 2025 Cost impacted by operational challenges  Robust order inflow¹ of USD 357 million resulting in a total order backlog¹ of USD 679 million, a Y/Y increase of 52% Dividend of USD 0.155 per share to be paid in Q4 2026“The third quarter saw strong contract activity across both the 3D streamer vessel fleet and the Ocean Bottom Node (OBN) operations, resulting in...

Nokia CorporationInterim report22 October 2026 at 08:00 EEST Nokia Corporation Interim Report for Q3 2026 Nokia delivers strong net sales and profit growthQ3 net sales grew 9% y-o-y on a constant currency basis (+10% reported). Network Infrastructure net sales grew 15% y-o-y on a constant currency basis, led by IP Networks growing 43% and Optical Networks 18%. Group net sales to AI & Cloud customers grew 123% and order intake 118%. Mobile Infrastructure net sales grew 5% y-o-y, in part due to acceleration of revenue from Q4 into Q3. The segment benefited from product mix, commercial discipline and continued execution of the cost reduction program. Q3 comparable gross margin was largely stable y-o-y at 44.6%. Reported gross margin declined 220bps to 42.2%. Q3 comparable operating margin increased 220bps y-o-y to 11.7% benefiting from...

2026 9M SalesPress release – Paris, October 22nd, 2026  Resilient nine-month performance, driven by America and EMEA, despite softer consumer demand in Q3 2026 9M Sales at €888m, remaining broadly stable on an organic1 basis (-0.2%) compared to 2025 (€896m)Organic sales growth in America (+8.6%) and in the EMEA region (+5.5%); sales stabilization in Asia‑Pacific; decline in France (-10.4%), impacted by a weak consumption environment and the contraction of the store network (BHV‑SGM) Like‑for‑like growth in all regions outside France, supported by America, helping Group’s like‑for‑like sales growth of +0.7% 2026 Q3 Sales at €291m, organic decline of -2.0% compared to Q3 2025 (€294m)Continued strict full‑price strategy, with a 2-point reduction in the average discount rate compared to 2025. The improvement was observed across...